Guardant Health Inc. (5GH)
XDUS
Closed
Oct 21, 2026
Day's Range
143.8652 wk Range
57.54Overview - 5GH - Guardant Health Inc.
Key Statistics
Valuation
Enterprise Value
1.33B
P/E (Trailing)
‪-45.10‬
PEG Ratio
‪-3.60‬
Price / Book
‪-89.27‬
EV / EBITDA
‪-3.56‬
Profitability
Gross Margin
‪65.38%‬
Profit Margin
‪64.46%‬
Operating Margin
‪-42.12%‬
Return on Assets
‪-20.67%‬
Return on Equity
‪419.18%‬
Ownership
Shares Outstanding
133.61M
Price stats
50-Day Avg
‪145.39‬
200-Day Avg
‪108.73‬
Peers - 5GH - Guardant Health Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on XDUS.
- 5GHXDUSGuardant Health Inc.+64.22%52-week change-45.10P/E (Trailing)‪64.46%‬Profit Margin
- NL0XDUSGRAIL, Inc.+53.52%52-week change-10.50P/E (Trailing)‪-236.94%‬Profit Margin
- 0MEXDUSTwist Bioscience Corporation+80.08%52-week change-108.42P/E (Trailing)‪50.72%‬Profit Margin
- 1K9XDUSCareDx, Inc.+77.16%52-week change-137.50P/E (Trailing)‪67.55%‬Profit Margin
- ILUXDUSIllumina, Inc.+65.36%52-week change44.52P/E (Trailing)‪66.08%‬Profit Margin
- 1HMXDUSAdaptive Biotechnologies Corporation Common Stock+52.26%52-week change-64.18P/E (Trailing)‪74.23%‬Profit Margin
- 04XXDUSPersonalis Inc.+51.53%52-week change-15.62P/E (Trailing)‪22.65%‬Profit Margin
Profile Summary - 5GH - Guardant Health Inc.
About
Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests, data sets, and analytics to support cancer detection and treatment decisions. Its product portfolio includes liquid biopsy tests for tumor mutation profiling, molecular residual disease monitoring, tissue-based genomic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Charting by TradingView.
Last updated:
